INTRAMYOCARDIAL BONE MARROW STEM CELLS IN PATIENTS UNDERGOING CARDIAC SURGICAL REVASCULARIZATION.
Bone marrow stromal/stem cells (BMSCs) remain a promising potential therapy for ischemic cardiomyopathy. The primary objective of this study was to evaluate the safety and feasibility of direct intramyocardial injection of autologous BMSCs in patients undergoing transmyocardial revascularization (TMR) or coronary artery bypass graft surgery (CABG). A phase I trial was conducted on adult patients suffering from ischemic heart disease with depressed left ventricular ejection fraction who were scheduled to undergo TMR or CABG. Autologous BMSCs were expanded for three weeks prior to scheduled surgery. Following completion of surgical revascularization, BMSCs were directly injected into ischemic myocardium. Safety and feasibility of therapy were assessed. Cardiac functional status and changes in quality of life were evaluated at one year. Fourteen patients underwent simultaneous BMSC and surgical revascularization therapy (TMR+BMSCs = 10, CABG+BMSCs = 4). BMSCs were successfully expanded and no significant complications occurred as a result of the procedure. Regional contractility in the cell-treated areas demonstrated improvement at 12 months compared to baseline (TMR+BMSCs Δ strain: -4.6% ± 2.1%; P = 0.02. CABG+MSCs Δ strain: -4.2% ± 6.0%; P = 0.30). Quality of life was enhanced, with substantial reduction in angina scores at one year post-treatment (TMR+BMSCs: 1.3 ± 1.2. CABG+MSCs: 1.0 ± 1.4). In this phase 1 trial, direct intramyocardial injection of autologous BMSCs in conjunction with TMR or CABG was technically feasible and could be performed safely. Preliminary results demonstrate improved cardiac function and quality of life in patients at one year after treatment.